Low-grade serous ovarian carcinoma (LGSC) is typically diagnosed in younger women and response to platinum-based chemotherapy regimens is poor. In contrast with high-grade serous ovarian carcinoma, LGSC is typically TP53 wild-type and more commonly harbor RAS/RAF mutations, suggesting that LGSC patients may derive clinical benefit from MAPK pathway targeted agents.
Statement of Translational Relevance
Low-grade serous ovarian carcinoma (LGSC) is typically diagnosed in younger women and response to platinum-based chemotherapy regimens is poor. In contrast with high-grade serous ovarian carcinoma, LGSC is typically TP53 wild-type and more commonly harbor RAS/RAF mutations, suggesting that LGSC patients may derive clinical benefit from MAPK pathway targeted agents.
LGSC is often characterized by association with serous borderline tumors, however we found that histological features alone, such as a borderline component and histological grade, are not reliable indicators of Ras-pathway activation. Rather, dichotomization of serous ovarian carcinomas based on underlying molecular aberrations is needed to improve the selection of ovarian cancer patients that may benefit from novel pathway targeted agents. In addition, we found that activating mutations in NRAS contribute to the spectrum of RAS/RAF mutations that define LGSC.
Furthermore tumors with NRAS mutations appear to be on an obligate path to carcinoma unlike tumors with other RAS/RAF mutations. 
INTRODUCTION
Recent molecular and pathological studies have led to a significantly changed understanding of the subtypes of epithelial ovarian cancer (1) . Serous epithelial ovarian carcinomas are the most common, and have been traditionally classified as high-or low-grade using morphological criteria in either a two-or three-tier grading system (2, 3) . Most high-grade serous carcinomas (HGSC) are thought to develop from secretory cells of the distal fallopian tube (4) and possibly ovarian inclusion cysts. TP53 mutations are almost ubiquitous in high-grade serous cancer and BRCA pathway disruption is common (5) (6) (7) (8) . By contrast, low-grade serous carcinomas (LGSC) typically have wild-type TP53 (9) and are thought to arise in a step-wise fashion from a subset of serous borderline tumors (SBT). Activating mutations of the MAP kinase pathway are present at a high rate in both SBT and LGSC (10) (11) (12) (13) (14) .
Up to 60% of LGSC are associated with SBT (2) and although more common in LGSC, a morphologic continuum between areas of SBT and invasive carcinoma has also been observed in HGSC cases. A review of 100 tumors reported areas of SBT in 2% of high-grade cases (2). Boyd and McCluggage described two cases (15) . Dehari et al (16) identified three cases of high-grade carcinoma associated with SBT (from 210 serous ovarian tumors) and in two cases mutation analysis showed the same KRAS mutations in both components, indicating a clonal relationship.
SBT has been reported to recur as high-grade carcinoma, albeit in a small number of patients (17) .
Collectively, these studies indicate that HGSC with associated borderline histology are uncommon.
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The frequent presence of activating mutations in KRAS and BRAF suggests that treatment strategies that target the MAPK pathway may be of benefit to this subset of patients (21) . The MEK inhibitor, Selumetinib, has shown some activity in patients with LGSC (22) and dual blockade of MAPK and PI3K/AKT pathways may be an effective strategy (21, 23) . However, the low incidence of LGSC represents a challenge to the conduct of definitive clinical trials, and there is an imperative to better define the subset of ovarian cancer patients that may benefit from targeted treatment.
In this study we sought to determine whether the presence of areas of adjacent borderline tumor was a reliable indicator of Ras-activated ovarian cancer, even in high-grade invasive cases. We present here the most comprehensive analysis to date of the clinical and molecular features of invasive ovarian cancer with co-existing regions of SBT. Our findings underscore the need to classify invasive ovarian tumors based on molecular features rather than morphology alone. 
METHODS

Cohort Selection
The study cohort was selected from review of 1,238 cases from the Australian Ovarian Cancer Study (AOCS) and a hospital-based series from Westmead Hospital, Sydney (Gynaecological Oncology Biobank at Westmead, GynBiobank). The AOCS recruited women with invasive or borderline ovarian, primary peritoneal or fallopian tube cancer across Australia from [2002] [2003] [2004] [2005] [2006] (http://www.aocstudy.org). Pathology review to confirm histological subtype and to reassign as Grade 1, 2 or 3 according to standardized criteria (3) was undertaken by a panel of specialist gynaecological pathologists. At the time the cohort was selected for the current study, 572 cases had been reviewed, either by review of a single, representative slide or review of a full set of diagnostic slides (136 cases). The review was undertaken using a synoptic report form and the presence of coexisting ovarian pathology, including borderline areas (categorized by a coarse papillary architecture with hierarchical branching, tufting and mild nuclear atypia of the epithelial cells without invasion) was systematically recorded. Additional cases were selected from the GynBiobank (patients diagnosed between 1990-2010), based on diagnostic pathology reports and pathology review. Grade information available on these cases was also according to a Grade 1-3 system in routine clinical use. Cases treated with neo-adjuvant chemotherapy were excluded (n=16).
The final study population consisted of three groups (i) 102 patients with serous epithelial ovarian cancer (EOC) with co-existing serous borderline tumor (designated SBT-EOC to denote their mixed features); (ii) 104 patients with serous carcinoma without co-existing SBT, ie a subset of AOCS cases which had centralized pathology review of all diagnostic slides in which no co-existing SBT was identified; (iii) 53 patients with SBT only, with no indication of invasive disease, randomly selected from SBT cases with frozen tissue specimens available enrolled in AOCS. See Figure S1 for additional details on cohort selection. 
Supplementary Information and Supplementary
Sample preparation -cryosection, microdissection, RNA & DNA extraction
Cryopreserved tumor samples were sectioned, stained, and reviewed by a gynaecological pathologist (RS) to confirm the presence of SBT and/or invasive cancer. Samples with <70% tumor were enriched by needle-or laser-microdissection. Where co-existing borderline and invasive disease was present on the same section, each area was isolated by microdissection. RNA and DNA were extracted using AbsolutelyRNA microprep kit (Stratagene, Agilent Technologies, Santa Clara, CA, USA) and DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany), respectively. RNA quality was assessed using Agilent BioAnalyzer (Agilent Technologies). For some cases, DNA was extracted from deparaffinized sections of formalin-fixed paraffin embedded (FFPE) specimens using a modified protocol of the QIAmp DNA FFPE Tissue kit (Qiagen). See Supplementary Methods for further details on sample preparation from cryopreserved and paraffin embedded sections.
Inclusion of paired cases in specific molecular analyses described below was dictated largely by the presence of borderline and invasive regions in the frozen or FFPE material available for research.
Supplementary Table S1 summarizes the samples included in each analysis.
Mutation screening
DNA was obtained from both the borderline tumor and invasive regions of some SBT-EOC ('paired' samples) in which both morphological regions were accessible in single fresh frozen or FFPE sections. In other cases, either borderline or invasive regions ('unpaired' samples) were obtained from a given sample (details in Supplementary Table S1). DNA from paired samples was screened for mutations in oncogenes and tumor suppressor genes using the Sequenom/OncoMap3 
DNA copy number -SNP Arrays
DNA from paired and unpaired SBT-EOC cases were analysed for copy number aberrations (CNA) using Illumina 610-Quad SNP or OmniExpress SNP arrays (Supplementary Table S1 ). 
Gene Expression Profiling
The gene expression profile of paired SBT-EOC cases (Supplementary Table S1 ) was determined using Affymetrix Hu-Gene ST 1.0 arrays (Affymetrix) arrays according to manufacturer's instructions. Raw data is available from GEO (GSE57280). Data were normalized using the RMA method available in the R package (30). Gene set enrichment analysis was also performed using all available genes sets from MSigDB (Broad Institute) (31).
Immunohistochemistry
Formalin-fixed paraffin embedded tissues were sectioned (4 μm), stained with monoclonal antibodies for progesterone receptor A (clone 16, Leica Microsystems, Wetzlar, Germany) and progesterone receptor B (clone SAN27, Leica Microsystems) using methods previously described (32). A gynecological pathologist (RS) identified a minimum of five high-power fields in the SBT and invasive compartments of stained tumors for quantitation using the Aperio Positive Pixel algorithm (Aperio Technologies, Vista, CA USA). Data was presented as percentage positive pixels.
Clinical Data Definitions
Progression-free survival was defined as the time between the date of histological diagnosis and the first confirmed sign of disease recurrence or progression based on definitions developed by the Gynaecological Cancer Intergroup, as previously described (33). In the majority of cases the date of progression was assigned using CA125 criteria. In cases where CA125 was not a marker of disease, or progression preceded an increase in CA125, relapse was based on imaging (appearance of new lesion), or, in a minority of cases, global deterioration in health status attributable to the disease, or death. Overall survival was calculated from the date of histological diagnosis to the date of death and censored at last contact date if the patient was alive.
Statistical Analyses
Associations between clinical variables were determined using the Chi-square test for significance or analysis of variance. Differences between progression-free or overall survival were statistically assessed using Cox regression and Kaplan-Meier curves with log-rank test. Statistical analyses were performed using Stata 10.0 (StataCorp LP, TX, USA). 
RESULTS
Serous borderline histology is associated with serous invasive cancer of all grades
We reviewed the diagnostic pathology reports of 967 serous invasive ovarian cancer cases from the Australian Ovarian Cancer Study (AOCS) and identified 33 with co-existing borderline histology, including nine Grade 3 cases. We suspected that co-existing borderline was less likely to be reported when high-grade disease was present, since the latter is the most clinically relevant feature.
Systematic pathology review had been undertaken for 572 AOCS patients. Details of co-existing pathology, including borderline tumors, was specifically requested on the pathology review form and we identified 31/572 (5.4%) cases with borderline regions. Of the 572 reviews, most were undertaken on a single, representative slide, however 136 were on a full set of diagnostic slides, and of these, 16 were found to have borderline regions, seven of which were only identified through pathology review. This suggests that the frequency of co-existing borderline may be as high as 12% Figure S1 ). Our systematic review of this very large cohort of serous ovarian carcinoma cases showed that serous borderline histology could be found in association with Grade 1, 2 or 3 invasive disease (Table 1) , in contrast to the prevailing view that it is primarily restricted to
LGSC. Figure 1 shows the typical appearance of co-existing borderline histology with invasive cancer across Grade 1-3 cancers.
Clinical features of SBT-EOC compared with serous EOC without co-existing borderline histology.
To determine whether serous tumors with or without borderline histology had distinct clinical behaviors, we considered clinico-pathological features, including progression-free and overall survival, in SBT-EOC versus a comparator cohort of 104 patients with serous EOC without co- Figure 3) . The difference in pre-treatment CA125 between SBT-EOC and EOC without adjacent SBT was independent of grade (p<0.012). Additionally patients with SBT-EOC had a longer median progression-free (p<0.0001) and overall survival (p<0.0001) compared with EOC with no adjacent SBT ( Table 1 , Supplementary Figure 4) .
However, the presence of borderline regions (ie SBT-EOC vs EOC) was not a significant predictor of survival in multivariate Cox regression including age, stage, grade and residual disease.
We focused particularly on the clinicopathological characteristics and survival of Grade 3 SBT-EOC to see if these lacked the characteristics of typical platinum-responsive, Grade 3 serous carcinoma (HGSC). As we had seen with the overall cohort, Grade 3 SBT-EOC were more often early stage (p<0.01, Table 2 ), although the majority had late stage disease. There was no difference in age, pre-treatment CA125 levels, residual disease, or median progression-free survival of Grade 3 tumors with or without associated SBT (Table 2) . While there was a trend for Grade 3 SBT-EOC cases to have better overall survival, this did not reach statistical significance (Table 2 , Supplementary Figure 5) . Therefore, the phenotypic difference between tumors with or without associated borderline histology was not matched by marked differences in clinical outcome.
Molecular analysis suggests clonal relationship between borderline and invasive regions of SBT-EOC pairs
To determine whether the co-existence of borderline and invasive regions represented independent collision tumors, or whether they had a common origin, we analyzed gene expression, DNA copy number and mutations in targeted genes. A subset of SBT-EOC cases with available biospecimens (n=58) was used for molecular analysis. The clinicopathological characteristics of this subset did not differ from the whole cohort (Supplementary Table S4 ).
Genomic copy number alterations were determined in paired borderline and invasive samples from and TP53 and also screened 124 commonly mutated cancer genes using mass spectrometry analysis (OncoMap3 Extended, Supplementary Table S2) in seven microdissected pairs. Across paired cases, mutually exclusive mutations were detected in 13/14 cases (KRAS, n=3; NRAS, n=3; TP53, n=7 mutations), (Table 3) 
SBT-EOC, so that combined with the 3 initial cases, the frequency of activating NRAS mutations was 5/58 (9%) invasive tumors with adjacent borderline malignancy. Whereas BRAF and KRAS mutations were found in both SBT and SBT-EOC tumors (Supplementary Tables S5A and S5B) , no NRAS mutations were found in any of the 53 purely SBT tumors tested. NRAS mutations were found in both Grade 1 and Grade 2 tumors (Table 5 and Supplementary Tables S5A and S5B ).
Patients with an NRAS mutation were older, had a higher proportion of late stage disease and more residual disease than patients with KRAS or BRAF mutations, however these trends did not reach statistical significance (Table 5 ). Pre-treatment serum CA125 levels were significantly lower in patients with NRAS mutated tumors ( Table 5, Table S6) , albeit with a relaxed false discovery rate (5%) to allow for the small sample size. Genes with the largest fold change (≥ 1.5) included Progesterone Receptor (PGR), which was more highly expressed in the borderline compartment, and SPTSSB, DDIT4, COL12A1 and FAM153C, which were more highly expressed in the invasive regions. PGR was selected for validation. It is expressed in most SBT (37) and in ~30% of serous EOC (38) 
DISCUSSION
There is an increasing awareness of the molecular differences between various ovarian cancer histological subtypes and the need for subtype-specific therapies. Here we sought to clarify the nature of serous carcinoma with adjacent borderline tumor, and to determine whether this pathological feature could be a reliable clinical indicator of Ras-driven cancers. We analysed 102 cases of SBT-EOC identified from >1200 patients with serous invasive ovarian cancer. Full pathology review of 136 cases suggested that SBT-EOC may comprise ~12% of serous invasive tumors, which is higher than previous estimates (2, 16, 17) . The distribution of histological grades amongst the 102 SBT-EOC was approximately equal ( Table 1 ). The relatively high proportion of distinguishable based on histology. This, and similar molecular data may be needed to resolve the classification of Grade 2 tumors into 'low' or 'high' grade (39) Although KRAS/BRAF and TP53/BRCA mutations are very common in low and high molecular grade tumors, respectively, they are not seen in all cases, possibly as other pathway-related events, such as the NRAS mutations, remain to be defined. Of the changes that characterize low and high molecular grades, pathogenic TP53 mutations appear to be the most indicative of molecular subtype. In our series, TP53 mutations were almost always accompanied by the extensive DNA copy number change typical of HGSC (42) (44); and one case of LGSC from which a cell line has also been derived (45) . In the paired samples tested, both the invasive and adjacent borderline compartments contained the same NRAS mutation. However, we did not identify any NRAS mutations in a cohort of 53 SBT without invasive disease. By contrast, mutations in BRAF and KRAS were found more often in SBT than in invasive disease. These data suggest that NRAS may be an important oncogene for the progression of SBT to frankly invasive disease. Indeed NRAS is a recognized oncogene in other cancer types, including leukaemia and melanoma (46, 47) and mutant NRAS was identified in an in vitro retroviral expression library screen for ovarian oncogenes (48) . The role of NRAS mutations in ovarian cancer warrants further investigation given emerging, individualized therapy targeting either NRAS specifically or its downstream effectors (49) .
There are several potential models of the evolution of tumors with adjacent borderline features that are consistent with the molecular data presented here. The first is that borderline tumors arise in association with a spectrum of alterations and specific molecular 'drivers' pre-determine pathogenesis. Specifically, a borderline tumor that is associated with a BRAF V600E mutation may be more likely to remain a borderline tumor and in only rare cases progress to carcinoma, whereas a borderline tumor that is associated with a TP53 or NRAS mutation, is on an obligate path to carcinoma; those with NRAS mutations resulting in Grade 1 or Grade 2 features, while those with TP53 mutations result in high-grade tumors with genomic instability and widespread copy number
alterations. An alternative hypothesis for the development of high-grade serous invasive cancer with adjacent SBT is that the SBT component is not a precursor lesion, but is part of the invasive tumor that morphologically resembles SBT, representing a better differentiated component (15) . If so, we would expect to see no genome-level difference (point mutation, copy number change) between the SBT and invasive components of SBT-EOC tumors, but may see differences in gene expression consistent with differentiation. We favor the latter explanation, since copy number and point mutation changes were shared, whereas expression of a small number of genes including progesterone receptor differed, between the SBT and EOC components of the same tumor. In particular, we found no evidence that HGSC with adjacent SBT arise through progression from low-grade tumors. If so, we would have expected that high-grade SBT-EOC would have the same spectrum of mutations present in low-grade SBT-EOC, plus additional genomic changes that render them high-grade. Our data are not consistent with this hypothesis since we found the presence of KRAS/BRAF/NRAS mutations and TP53 mutations to be mutually exclusive. Similarly, the presence 
